The present study still adds important information regarding the prevalence of arrhythmias in a patient group with T2DM and without treatment with SGLT2 inhibitors and or GLP-1 RAs which is important not the least since many patients with a diagnosis of T2DM are not treated with such drugs. The gene discussed is SLC5A2; the disease is cardiac arrhythmia.